All asthma phenotypes were associated with risk for severe Covid-19 outcomes, except for type-2 inflammation, reveals a recent study. In the latest study analysing the effect of asthma phenotype on COVID-19 outcomes and also to compare rates of COVID-19 hospitalization with influenza and pneumonia, a team of researchers led by Chloe I. Bloom, senior clinical research fellow at Imperial College London, observed that these phenotypes were also significantly associated with hospitalizations for influenza and pneumonia. 

 The study, published in the American Journal of Respiratory and Critical Care Medicine, included 434,348 adults with asthma and 748,327 matched individuals in the UK, who were identified using electronic medical record data. The researchers said that their research underlines increased healthcare-seeking behaviour and GPS and a lower threshold to diagnose COVID-19 in asthmatic patients. They also added that contrary to expectations, atopy and blood eosinophil counts were not associated with more severe COVID-19 outcomes.